Our team

Gerard holds a degree in Biochemistry from the University of Barcelona. He made his final degree project in the Molecular Neurobiology group of his faculty where he studied the heteromerization of dopamine and adrenaline receptors in CNS. After graduation, he pursued a Postgraduate degree in Project Management for New Drug Development at the same university. Gerard joined SOM Biotech as Junior Scientist in January 2019, and is currently involved in the research and development of early stage projects.

Aileen is a pharmacist by training. She holds a Master in Molecular Biotechnology degree from the University of Barcelona and interned at SOM Biotech giving support to the R&D Unit. Her master project called “Drug Repositioning for Rare Diseases” was based on the definition and execution of new promising internal projects. She finally joined the company as Junior Scientist in 2016 and is now a Project Manager responsible for several early stage programs.

Luca obtained his bachelor´s degree in Pharmaceutical Biotechnologies from the University of Bari, Italy. He then moved to The Netherlands, where he obtained a master´s degree in Molecular Medicine and a PhD in Biochemistry from the University of Rotterdam. During his doctorate he investigated the properties of microtubule-associated proteins through wet-lab and computational approaches. After his PhD, he was a guest researcher at the University of Innsbruck, Austria, where he worked on the identification of environmental endocrine disruptors through pharmacophore modelling, virtual screening and docking studies. Luca joined SOM Biotech as Senior Computational Chemist in May 2018.

Gal·la obtained her degree in Chemistry from the University of Barcelona, Spain and a Master Degree in Organic Chemistry from the University of Bologna, Italy. She worked 3 years as a Synthetist at the University of Siena, and then joined the research center Siena Biotech as Senior Scientist for 9 years. She is a medicinal chemist with broad practical laboratory skills in classic organic synthesis and experienced in various stages of the small molecule drug discovery process. She also has experience as a project leader of a program focused on development of potential new drug molecules for CNS disorders, coordination of multidisciplinary teams, definition and implementation of project strategy and plans, reporting to the strategy and portfolio committees. Always eager to learn more about pharmaceutical topics, she worked for 2 years at the Hospital of Siena, coordinating research programs and projects within the rheumatology department. Gal·la joined SOM Biotech as R&D Manager in 2015.

Katja has a Master Degree in Economics (Rheinische Friedrich-Wilhelms University, Bonn) and is a “Certified EFFAS Financial Analyst” with more than 20 years of experience in Investor Relations, Corporate Development and Corporate Communication in blue chip European companies and SMEs of various sectors. Strong track record in structuring and execution of IPOs, as well as in drafting, implementation, and monitoring of corporate strategic plans, Investor Relations programs, corporate transactions, corporate communication and social responsibility initiatives, including crisis management and complex corporate situations.

Maria obtained a PhD in Biotechnology in Russia. During 4 years she was working as Business Development Project Manager at Research Institute of Biotechnology in Russia, where she was helping to accelerate the development of research projects in the field of Biotechnology from research to the market. To obtain experience of work on the international level, she earned Boehringer Ingelheim Fonds Scholarship and Russian Federation President Scholarship for the internship at the Department of Genetics at the University of Barcelona. After one year of the internship, Maria continued her scientific career at Institute for Bioengineering of Catalonia, where she was working during 2 years on an investigation of mechanisms of bacterial virulence and antimicrobial compounds against multidrug-resistant bacterial infections. Because she always was interested in obtaining financial and business knowledge in the Pharmaceutical industry, in 2018, she started an MBA at Biotechnology Business Institute, University of Barcelona. Maria joined SOM Biotech in April 2019.

Mireia obtained her bachelor’s degree in Tourism from the University of ESADE in Barcelona, Spain. She has worked as an administrative assistant for more than 5 years in Nestlé, including 2 years of experience at the headquarters in Switzerland, where she became instrumental in building an international team of more than 50 FTE in a hub located in Barcelona. She is proactive and a strong team player, and she likes challenges and dynamic organizations. Mireia joined SOM Biotech in October 2018 as Office Manager.

Oscar holds a degree in Chemistry from the University of Barcelona and a degree in Biochemistry from the University Autonoma de Barcelona, and a Master degree in Computational Chemistry. His research was focused in computer aided drug design in Alzheimer and in Phosphodiesterase inhibitors. He has more than 7 years of experience in virtual drug design by using different computational tools in the drug discovery process as well as working in in-silico platforms, and as R&D Manager. He has also attended Courses in Regulatory Affairs and Patents. Oscar joined SOM in 2012 and he is responsible for the company artificial intelligence drug discovery computational system.

Núria is a biochemist with a solid research experience both in the academic and the industrial settings.  After a PhD in Biochemistry and Molecular Biology at the University of Barcelona, she moved to Switzerland for postdoc studies in the field of host-pathogen interactions and immunology at the École Polytechnique Fédérale de Lausanne (Switzerland), with a long-standing collaboration with Yale University (CT, USA).  She then joined Xigen SA, a Swiss biotechnology company specialized in inflammation, as Senior Scientist in Discovery Research.  She contributed to the development of XG104 and brimapitide, currently in Phase 2 and Phase 3 development for ocular indications, respectively. Núria joined SOM Biotech in 2010 initially as project manager and later as R&D Manager.  Among the different projects she has been involved in at SOM Biotech, she has been responsible for the development of SOM0226, a repositioned compound for the treatment of Transthyretin Amyloidosis that was successfully licensed after a Phase 2 proof of concept study. She has managed the company IP portfolio and contributed to 5 patents, 12 research and review articles and 11 presentations in international meetings.

Saurabh is passionate about valuation and corporate finance and his expertise lies in valuing early stage companies and products that has several uncertainties involved in the life cycle. Having worked with several young life sciences companies in the areas of finance, he provides a strong financial perspective to the strategic decisions taken by the Board and intends to position himself as a Value Integrator to the CEO to drive long term growth of the company. Besides, his areas of interest include Real Options and Decision trees framework that captures the management’s flexibility in the times of uncertainty. He is the founder of Farmantra, a life sciences corporate finance advisory firm and an Independent Expert at European Commission. He has worked in the USA and India before embarking on his entrepreneurial venture in Spain and has an MBA from ESADE Business School.

Kevin McAllister has worked in the pharmaceutical industry for over 30 years.  Kevin joined the preclinical Nervous System research department of Sandoz and held positions of increasing responsibility up to Executive Director in Neuroscience at Novartis Institutes for Biomedical Research. Following this, Kevin worked as Principal Medical Scientific Expert in the Neuroscience Clinical Development Franchise where he contributed to projects with both pre- and post-marketing approval.  Kevin is Managing Director of Neurenable GmbH, a company dedicated to enable Neuroscience drug discovery and development. Kevin holds a PhD from the University of Wales, UK, and an MBA from the International Institute for Management Development, Lausanne, Switzerland.

Dr. C. Scart has more than 25 years of in-depth experience in the development and life-cycle management of innovative medicinal products in multinational pharmaceutical companies such as Janssen Cilag, Glaxo Wellcome, Recordati and CSLBehring as Clinical Development physician and Medical Director. Then she joined small biotechs (Pharnext as CMO, and Bioprojet as Head of Clinical Development) leading multi-national clinical development programs from Phase I to Phase IV across a broad range of therapeutic areas (mainly in neurology and rare diseases) and providing support for regulatory filings and interactions with FDA, EMA, and national regulatory authorities.
Her Professional education as a Medical Doctor certified in Pediatrics also includes postgraduate Master’s degrees in Public Health (Pierre et Marie Curie Paris VI Medicine University), and in the Methodology of therapeutic evaluation (Lariboisière Paris VII Medicine University).

Dr. Insa has worked for more than 20 years in multinational pharmaceutical companies such as Parke-Davis (now Pfizer), UCB Pharma, Uriach Group (now Palau Pharma) and ISDIN (from Esteve Group), before establishing SOM Biotech. His experience is in drug development, from drug identification to commercialization, including clinical research and licensing. He was involved in the development of products like Quinapril, Tacrine, Cetirizin, Levetiracetam, Rupatadin, Dersalazine, Cimicoxib, Albaconazole, Gemfibrozil, Gabapentin, Piracetam, Levocetirizine, Nanocapsuled Cyclosporin, Disitertide, and others. He received his Medical training and his PhD in Clinical Neurology from the University of Alicante, Spain; an MBA from ESADE Business School in Barcelona and an Executive Education Program from IESE, Barcelona. He has also attended a couple of biotech leadership programs at Harvard Business School, Boston. His background includes more than 45 publications and papers, 7 chapters in books, 87 congress communications and 9 pharmaceutical patents.